| Autor: |
Goodman, Daire, Kennedy, Sharon, Cronin, Kevin, Dolan, Roisin, Titan, Ashley L., Chang, James, Megerle, Kai, Murray, Peter, Hammert, Warren |
| Předmět: |
|
| Zdroj: |
Journal of Hand Surgery (17531934); Dec2023, Vol. 48 Issue 11, p1246-1248, 3p |
| Abstrakt: |
The letter discusses the potential use of Botulinum toxin type A (BXT-A) in the management of chronic vascular disorders in the hand and upper limb, specifically focusing on Raynaud's phenomenon (RP). BXT-A is a neurotoxin that targets the SNAP25 protein to inhibit arteriole vasoconstriction and improve symptoms of RP. It has been used for nearly 20 years and has shown reductions in symptomatology lasting 2 to 4 months. The letter suggests that BXT-A can be used as a diagnostic aid in selecting patients for surgical intervention and highlights the importance of using validated patient-reported outcome measures to quantify the benefits. However, further research is needed to understand the mechanism of action, optimal dosing, and long-term effects of BXT-A. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
